Rheumatology Author Roy Fleischmann: Switching Between UPA and ADA

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.